No significant differences were observed between healthy controls and cancer patients regarding the frequency of major peripheral blood T cell subsets CD4+ (39.4% vs. 39.4%) and CD8+ (23.6% vs. 23.2%), total NK cells (13.4% vs. 13.8%) (Figure 1A), or CD8+ T cells expressing different KIR receptors, KIR2DL1+ (1.4% vs. 1.7%), KIR2DS1+ (0.4% vs. 0.36%), KIR2DL1/S1+ (0.04% vs. 0.04%), KIR3DL1+ (0.93% vs. 1.27%), KIR2DL2+ (3.05% vs. 2.16%), and KIR2DL3+ (3.82% vs. 4.37%) (Figure 1B). The gene discussed is CD4; the disease is cancer.